Article

Ablative Therapy for Barrett's Esophagus

The author of a study that compared the cost utility of ablation with that of endoscopic surveillance strategies explains his findings.

In this video from the American Gastroenterological Association, John M. Inadomi, MD, discusses the article "Ablative Therapy for Barretts Esophagus: A Cost-Utility Analysis.” The authors of the article compared the cost utility of ablation with that of endoscopic surveillance strategies. They concluded that endoscopic ablation “could be the preferred strategy for managing patients with Barrett's esophagus with high-grade dysplasia. Ablation might also be preferred in subjects with low-grade dysplasia or no dysplasia, but the cost effectiveness depends on the long-term effectiveness of ablation and whether surveillance endoscopy can be discontinued after successful ablation.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.